Compare Novo Nordisk A/S (NVO) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs VanEck Semiconductor ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while VanEck Semiconductor ETF trades at $603.33 (market cap $73.92B). The key difference: Novo Nordisk A/S is far larger — about 2.2× VanEck Semiconductor ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and VanEck Semiconductor ETF for 101 Days on average.
| NVO | SMH | |
|---|---|---|
Market Cap | $165.31B | $73.92B |
Volume | 11,432,838 | 11,050,892 |
Sector | Health | — |
52-Week High | $63.98 | $668.91 |
52-Week Low | $35.29 | $325.10 |
Typical Hold Time | 116 Days | 101 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
SMH (VanEck Semiconductor ETF) trades at $606.82, down 2.91% over the past day amid broader market volatility. The ETF maintains a bullish technical signal with strong moving average support, though oscillators are neutral. Recent news highlights semiconductor sector strength, with SMH up approximately 69% year-to-date in 2026, outperforming many individual stocks like Nvidia. The fund provides diversified exposure to chip leaders, benefiting from AI-driven demand and industry consolidation.
Outlook remains positive given structural growth in AI and semiconductor demand, but risks include high concentration in top holdings, sensitivity to tech sector volatility, and geopolitical trade tensions. Investors should weigh the ETF's historical outperformance against potential reversion risks as valuations stretch.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
